Compare Summit Therapeutics Inc (SMMT) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Unity Software Inc — how do they compare? Summit Therapeutics Inc trades at $15.35 (market cap $11.87B), while Unity Software Inc trades at $43.65 (market cap $18.97B). The key difference: Unity Software Inc is the larger of the two by market cap, and Unity Software Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | U | |
|---|---|---|
Market Cap | $11.87B | $18.97B |
Sector | Health | Technology |
52-Week High | $26.98 | $49.47 |
52-Week Low | $12.55 | $17.13 |
Enterprise Value | $11.20B | $18.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.96, up 3.1% today, but faces bearish technical signals with negative ROE of -192.5% and net income of -$1.08B for 2025. The company's key catalyst is the FDA review of ivonescimab with a November 2026 decision, supported by expanded clinical trials in bladder and kidney cancer. Cash flow remains dependent on financing activities, with operating cash flow negative at -$323M in 2025.
Investment outlook hinges on ivonescimab's FDA approval, with analyst consensus target at $27.90 offering significant upside. However, high execution risk, ongoing losses, and fiduciary investigations present substantial downside. The stock represents a high-risk biotech speculation with binary outcomes based on regulatory success.
Unity Software (U) trades at $43.00, up 5.37% today, with strong technical momentum and bullish analyst sentiment. The stock shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 24% year-over-year, and narrowing losses. Recent news highlights Vector advertising platform momentum and accelerated AI integration driving optimism.
The outlook remains positive with 69% analyst buy ratings and $47.45 consensus price target, though risks include persistent net losses, high valuation multiples, and competitive pressures. Continued execution on profitability timeline and Vector platform growth are key catalysts for further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
